Navigation path



Preclinical Studies towards an Affordable, Safe and Efficacious Two-Component Paediatric Malaria Vaccine
Framework programme:
Project number:
EC contribution:
€ 2,345,358
48 months
Starting date:
1st February 2007
Web site:

Keywords: Malaria, rBCG, rAd35, paediatric vaccine


Malaria is one of the major public health challenges in the world, causing more than one million deaths each year. The disease primarily affects children of the developing world. The available measures, such as personal protection or drugs, have proven insufficient to control the disease. A safe, affordable and efficacious paediatric malaria vaccine, which fits in the existing WHO Expanded Programme on Immunisation, would alleviate tremendous suffering in human kind.

Taking up this challenge, the PRIBOMAL consortium proposes to generate and test in preclinical models the safety and efficacy of an innovative malaria vaccine. The vaccine consists of a prime, to be administered at birth, of a novel recombinant BCG vector carrying preferentially multiple antigens derived from the Plasmodium falciparum parasite, the cause of malaria. The priming vaccine is followed at week 14 after birth by a booster vaccination using industrially developed, recombinant adenoviral vector carrying the identical Plasmodium falciparum antigens as the rBCG-based malaria vaccine.

Generation of these novel vaccine candidates as well as testing in established and novel pre-clinical models to determine potency and safety requires a combined European effort to bring together the required expertise on basic parasite biology, malaria epidemiology, disease onset and progression, recombinant vector technology, fundamental immunology, advanced animal models, and sophisticated proteomics. The international PRIBOMAL consortium bundles all required experience and as such is well positioned to successfully conduct this research programme.

[+] Read More